

Glycemic traits and Alzheimer's disease: a mendelian randomization study

Yuesong Pan^{1,2}, Weiqi Chen^{1,2}, Hongyi Yan^{1,2}, Mengxing Wang^{1,2}, Xianglong Xiang^{1,2}

¹Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

²China National Clinical Research Center for Neurological Diseases, Beijing, China

Correspondence to: Yuesong Pan; **email:** yuesongpan@ncrcnd.org.cn

Keywords: Alzheimer's disease, glycemic traits, insulin resistance, mendelian randomization, diabetes

Received: June 1, 2020

Accepted: July 25, 2020

Published: November 16, 2020

Copyright: © 2020 Pan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Previous observational studies have reported an association between impaired glucose metabolism and Alzheimer's disease. This study aimed to examine the causal association of glycemic traits with Alzheimer's disease. We used a two-sample Mendelian randomization approach to evaluate the causal effect of six glycemic traits (type 2 diabetes, fasting glucose, fasting insulin, hemoglobin A1c, homeostasis model assessment- insulin resistance and HOMA- β -cell function) on Alzheimer's disease. Summary data on the association of single nucleotide polymorphisms with these glycemic traits were obtained from genome-wide association studies of the DIABetes Genetics Replication And Meta-analysis and Meta-Analyses of Glucose and Insulin-related traits Consortium. Summary data on the association of single nucleotide polymorphisms with Alzheimer's disease were obtained from the International Genomics of Alzheimer's Project. The Mendelian randomization analysis showed that 1-standard deviation higher fasting glucose and lower HOMA- β -cell function (indicating pancreatic β -cell dysfunction) were causally associated with a substantial increase in risk of Alzheimer's disease (odds ratio=1.33, 95% confidence interval: 1.04-1.68, $p=0.02$; odds ratio=1.92, 95% confidence interval: 1.15-3.21, $p=0.01$). However, no significant association was observed for other glycemic traits. This Mendelian randomization analysis provides evidence of causal associations between glycemic traits, especially high fasting glucose and pancreatic β -cell dysfunction, and high risk of Alzheimer's disease.

INTRODUCTION

Alzheimer's disease is a major and increasing global health challenge in elderly people without available curative treatment [1]. Although the pathophysiologic mechanism of Alzheimer's disease is largely unknown, impaired glucose metabolism in the brain may contribute to Alzheimer's diseases pathology [2]. Recently, several epidemiological studies have suggested that some modifiable risk factors, such as type 2 diabetes and insulin resistance, were associated with cognitive decline or Alzheimer's disease [3–7]. However, positive association was not observed in another study [8]. Furthermore, observational studies

might be confounded by potential confounders and reverse causation [9]. Whether the association between glucose metabolism and Alzheimer's disease observed in observational studies reflect causal association needs further investigation. Therefore, the causal association between impaired glucose metabolism and Alzheimer's disease is still controversial.

Mendelian randomization (MR), using genetic variants as instrumental variables, is a method that enables strong causal inference between a risk factor and a disease [9]. In this study, we aimed to use MR analysis to evaluate the causal association between glycemic traits and Alzheimer's disease.

RESULTS

The inverse-variance weighted (IVW) method showed that 1-standard deviation (SD) higher fasting glucose and lower HOMA- β -cell function (HOMA- β) (indicating pancreatic β -cell dysfunction) were causally associated with a substantial increase in risk of Alzheimer's disease (odds ratio (OR)=1.33, 95% confidence interval (CI): 1.04-1.68, $p=0.02$; OR=1.92, 95% CI: 1.15-3.21, $p=0.01$) (Figure 1). Similar association was observed in fasting glucose using the penalized robust IVW, weighted mode-based estimate (MBE) and Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) methods, but not using the MR-Egger, simple median and weighted median methods of MR analyses (Table 1). For HOMA- β , similar results were observed using the penalized robust IVW, simple median and MR-PRESSO methods, but not using the MR-Egger, weighted median and weighted MBE methods of MR analyses. The results of leave-one-out sensitivity analyses showed that the associations between fasting glucose, HOMA- β and risk of Alzheimer's disease were not substantially driven by any individual single nucleotide polymorphism (SNP). Association between each variant with fasting glucose, HOMA- β and risk of Alzheimer's disease are displayed in Figure 2. No significant association of genetically predicted type 2 diabetes, fasting insulin, hemoglobin A1c (HbA1c) and homeostasis model assessment-insulin resistance (HOMA-IR) with risk of Alzheimer's disease was observed using any MR method (Figure 1; Table 1).

MR-Egger regression showed no evidence of directional pleiotropy for the association of any glycemic trait with Alzheimer's disease (all p values for intercept >0.05) (Table 1). There was no evidence of heterogeneity in

the IVW analysis for fasting glucose ($Q=32.71$, $P=0.17$), fasting insulin ($Q=13.09$, $P=0.79$), HbA1c ($Q=45.20$, $P=0.12$) and HOMA- β ($Q=2.28$, $P=0.81$), but heterogeneity was observed for type 2 diabetes ($Q=67.91$, $P=0.007$).

DISCUSSION

Using two-sample MR analysis based on data from large-scale genome-wide association studies (GWAS), our study provided genetic evidence in supporting that glycemic disorder may lead to Alzheimer's disease. In the present study, genetically predicted higher level of fasting glucose and lower level of HOMA- β (indicating pancreatic β -cell dysfunction) were causally associated with an increased risk of Alzheimer's disease. However, no significant association was observed between type 2 diabetes, fasting insulin, HbA1c, HOMA-IR and risk of Alzheimer's disease. Sensitivity analyses with different statistical models showed almost similar results.

Impaired glucose metabolism, which is modifiable, contributes to Alzheimer's disease pathogenesis. It was even proposed that Alzheimer's disease may be a brain-specific form of diabetes mellitus, a "type 3 diabetes" [10]. However, the precise mechanisms involved in the association of glucose metabolism with cognitive decline and Alzheimer's disease are not yet fully understood. Several assumed mechanisms have been proposed. Hyperglycemia may induce increased peripheral utilization of insulin and reduce insulin transport into the brain, ultimately producing brain insulin deficiency [11]. Impaired glucose metabolism, such as type 2 diabetes and insulin resistance, may lead to impaired neuronal insulin signaling, neuroinflammation, oxidative stress, resulting in amyloid- β accumulation, tau hyper-phosphorylation and




Figure 1. Risk of Alzheimer's disease for genetically predicted glycemic traits. The associations are assessed using the inverse-variance weighted method. Estimates are per 1-unit higher log-odds of type 2 diabetes, 1-SD higher fasting glucose, fasting insulin and HOMA-IR, %-units higher HbA1c, and 1-SD lower HOMA- β (indicating pancreatic β -cell dysfunction). Trait values for fasting insulin, HOMA- β and HOMA-IR were naturally log transformed. CI, confidence interval; HbA1c, hemoglobin A1c; HOMA- β , homeostasis model assessment- β -cell function; HOMA-IR, homeostasis model assessment- insulin resistance.

Table 1. MR statistical sensitivity analyses.

| Glycemic traits | MR methods | Parameter | Associations with AD | |
|-----------------|----------------------|------------------|----------------------|---------|
| | | | OR/Odds (95% CI) | P value |
| Type 2 diabetes | Penalized robust IVW | OR | 1.01(0.96-1.07) | 0.65 |
| | | MR-Egger | 0.98(0.84-1.14) | 0.83 |
| | Simple median | Odds (intercept) | 1.00(0.99-1.02) | 0.63 |
| | | OR | 0.99(0.91-1.08) | 0.83 |
| | | OR | 0.99(0.91-1.07) | 0.73 |
| | | OR | 0.99(0.90-1.10) | 0.89 |
| | | OR | 1.03(0.97-1.10) | 0.35 |
| Fasting glucose | Penalized robust IVW | OR | 1.38(1.16-1.66) | <0.001 |
| | | MR-Egger | 1.36(0.78-2.38) | 0.28 |
| | Simple median | Odds (intercept) | 1.00(0.98-1.02) | 0.91 |
| | | OR | 1.44(0.96-2.17) | 0.08 |
| | | OR | 1.24(0.90-1.70) | 0.19 |
| | | OR | 1.33(1.01-1.75) | 0.04 |
| | | OR | 1.39(1.07-1.82) | 0.02 |
| Fasting insulin | Penalized robust IVW | OR | 1.34(0.81-2.21) | 0.25 |
| | | MR-Egger | 4.31(0.24-75.87) | 0.32 |
| | Simple median | Odds (intercept) | 0.98(0.94-1.03) | 0.39 |
| | | OR | 1.35(0.69-2.62) | 0.38 |
| | | OR | 1.33(0.70-2.55) | 0.39 |
| | | OR | 1.49(0.61-3.62) | 0.38 |
| | | OR | 1.24(0.83-1.87) | 0.31 |
| HbA1c | Penalized robust IVW | OR | 0.96(0.70-1.32) | 0.80 |
| | | MR-Egger | 1.21(0.55-2.64) | 0.64 |
| | Simple median | Odds (intercept) | 1.00(0.98-1.01) | 0.51 |
| | | OR | 0.85(0.51-1.40) | 0.52 |
| | | OR | 1.00(0.61-1.64) | 0.98 |
| | | OR | 0.96(0.55-1.67) | 0.87 |
| | | OR | 0.96(0.67-1.37) | 0.81 |
| HOMA-β | Penalized robust IVW | OR | 1.85(1.24-2.77) | 0.003 |
| | | MR-Egger | 0.91(0.22-3.79) | 0.90 |
| | Simple median | Odds (intercept) | 1.02(0.98-1.06) | 0.27 |
| | | OR | 2.06(1.04-4.05) | 0.04 |
| | | OR | 1.73(0.93-3.22) | 0.08 |
| | | OR | 1.68(0.92-3.06) | 0.09 |
| | | OR | 1.92(1.35-2.71) | 0.01 |

MR, mendelian randomization; AD, Alzheimer’s disease; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted; MBE, mode-based estimate; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; HbA1c, hemoglobin A1c; HOMA-β, homeostasis model assessment -β-cell function. Estimates are per 1-unit higher log-odds of type 2 diabetes, 1-SD higher fasting glucose and fasting insulin, %-units higher HbA1c and 1-SD lower HOMA-β (indicating pancreatic β-cell dysfunction). Trait values for fasting insulin and HOMA-β were naturally log transformed. Sensitivity analyses were not performed for HOMA-IR since these methods requires >2 variants.

subsequent cognitive decline and Alzheimer's disease [12, 13]. Recent studies showed that diabetes and insulin resistance were also associated with brain atrophy and aberrant functional connectivity [14, 15].

In the last decades, accumulating observational evidence has demonstrated that type 2 diabetes and insulin resistance were associated with cognitive decline or Alzheimer’s disease [3–7]. A meta-analysis showed

that diabetes mellitus was associated with a 1.6-fold higher risk of Alzheimer’s disease [3]. In the English Longitudinal Study of Ageing study with 5189 participants and 10-year follow-up, HbA1c levels and diabetes status were associated with long-term cognitive decline [4]. Other longitudinal studies from Finland also observed significant association between insulin resistance and long-term cognitive decline [6, 7]. However, the association was nonsignificant between

type 2 diabetes, insulin resistance or HbA1c and cognitive state or Alzheimer's disease in a recent British cohort study and previous MR analyses [8, 16, 17]. The present study further emphasized the causal effect of high fasting glucose, pancreatic β -cell dysfunction on high risk of Alzheimer's disease. This also indicated that the prediabetic stage could be a potential time-point for preventative treatment of Alzheimer's disease. This result was supported by a recent study with 34-year follow-up that found an U-shaped relationship between fasting insulin and dementia and excess risk for dementia in subjects with low level of insulin [18]. Potential explanation of the negative associations for

fasting insulin and HOMA-IR in our study included weak instruments and small sample size. Furthermore, this might be caused by that HOMA-IR mainly reflect hepatic insulin resistance instead of brain insulin resistance [19].

The strength of the study is the design of MR analysis based on large-scale GWAS studies. The MR design uses genetic variants as instrumental variables to estimate the association between an exposure and a disease. As genetic variants are randomly allocated at meiosis and independent of other factors that may bias observational studies, MR analysis is not prone to potential reverse causation and unmeasured confounders, such as dietary and lifestyle preference, and thus can strengthen the evidence for causal inference [9]. Using two-sample MR method, we were able to test the effect of glycemic traits on Alzheimer's disease based on data from a large-scale cohort (17,008 cases and 37,154 controls). Nevertheless, potential bias may exist due to the nature of two-sample MR method since data of associations of SNP-exposure and SNP-outcome were derived from 2 different populations. Results in previous one-way or two-way MR analyses showed nonsignificant association between type 2 diabetes or fasting insulin with Alzheimer's disease [16, 17, 20], but were not consistent for fasting glucose [16, 17, 21]. Another MR study found insulin sensitivity polygenic score formed from a subset of type 2 diabetes associated SNPs, but not the overall type 2 diabetes polygenic score, was causally associated with Alzheimer's disease [22]. Our study distinguished from previous MR studies [16, 17, 20–22] by comprehensive evaluation of six glycemic traits and strict selection of instruments via exclusion of SNPs with potential pleiotropic effects.

Our study has several limitations. First, our analyses were performed in the population of European ancestry and may not be generalized to those of non-European ancestry. However, recent studies provided evidence of shared genetic architecture for glycemic diseases across ethnic groups [23]. The uniformity of ancestry minimizes the risk of bias by population admixture. Second, the estimates may still be biased by potential for residual pleiotropy (SNPs affect the outcome via a different pathway other than the exposure) [24]. However, we had a strict exclusion of instruments with potential pleiotropy and pleiotropic effect was not observed in MR-Egger regression. Third, further studies with large sample size are needed since the results were not validated in some sensitivity analyses in our study.

In conclusion, our two-sample MR analysis provides evidence of causal associations between glycemic traits, especially hyperglycemia and pancreatic β -cell




Figure 2. Associations of fasting glucose (A) and HOMA- β (B) related variants with risk of Alzheimer's disease. The red line indicates the estimate of effect using inverse-variance weighted method. Circles indicate marginal genetic associations between fasting glucose, HOMA- β and risk of Alzheimer's disease for each variant. Error bars indicate 95% confidence intervals.

dysfunction, and high risk of Alzheimer's disease. However, validating and replicating these findings in large-scale studies is warranted.

MATERIALS AND METHODS

Study design

We designed a two-sample MR analysis to evaluate the causal effect of glyceic traits on Alzheimer's disease (Figure 3). The MR design assumes that the genetic variants are associated with glyceic traits, but not with other confounders, and the genetic variants are conditionally independent of Alzheimer's disease given glyceic traits and the confounding factors. Using the genetic variants as instrumental variables to assess the association between an exposure and an outcome, MR approach is a method that strengthens causal inferences and addresses susceptibility to potential confounding and reverse causation prone to conventional observational studies [9]. Six glyceic traits, including type 2 diabetes, fasting glucose, fasting insulin, HbA1c, HOMA-IR and HOMA- β , were evaluated. Data on the associations of SNPs with these glyceic traits and Alzheimer's disease were obtained from recently published large-scale GWAS (Table 2) [25–30]. The protocols of the original studies were approved by the institutional review board of participating sites and informed consents were obtained from all participants.

Instruments

Genetic variants which were associated with these six glyceic traits were obtained from previous published GWAS (Table 2). A total of 51 SNPs associated with type 2 diabetes were obtained from recently published two GWAS meta-analyses from the Diabetes Genetics




Figure 3. Conceptual framework for the Mendelian randomization analysis of glyceic traits and risk of Alzheimer's disease. The design assumed that the genetic variants are associated with glyceic traits, but not with confounders, and the genetic variants are associated with risk of Alzheimer's disease only through glyceic traits. SNP, single nucleotide polymorphism.

Replication And Meta-analysis (DIAGRAM) consortium [25, 26]. The first study combined the DIAGRAMv3 GWAS meta-analysis with a stage 2 meta-analysis of MetaboChip, including 34,840 cases and 114,981 controls, overwhelmingly (97.6%) of European ancestry [25]. In that study, 38 genetic loci with at least 1 genetic variant associated with type 2 diabetes were identified ($P < 5.0 \times 10^{-8}$). The second study was an expanded GWAS of type 2 diabetes in Europeans, including a GWAS stage 1 with a total of 26,676 type 2 diabetes cases and 132,532 control participants from 18 GWAS and a MetaboChip stage 2 with 14,545 type 2 diabetes cases and 38,994 controls from nonoverlapping 16 studies [26]. That study identified 13 novel type 2 diabetes -associated loci ($P < 5.0 \times 10^{-8}$).

SNPs associated with fasting glucose, fasting insulin, HbA1c, HOMA-IR and HOMA- β , were obtained from the recently published Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) [27–29]. MAGIC was a collaborative effort to combine data from multiple GWAS to identify loci that impact on glyceic and metabolic traits. In that GWAS meta-analysis, 36 genetic loci with at least 1 genetic variant associated with fasting glucose were identified in up to 133,010 non-diabetic participants of European ancestry from 66 studies, and 19 genetic loci with at least 1 genetic variant associated with fasting insulin in up to 108,557 individuals of European ancestry from 56 studies ($P < 5.0 \times 10^{-8}$) [27]. A total of 43 genetic loci with at least 1 genetic variant associated with HbA1c were identified in up to 123,665 non-diabetic individuals from 82 cohorts of European ancestry ($P < 5.0 \times 10^{-8}$) [28]. A total of 7 SNPs associated with HOMA- β and 2 SNPs associated with HOMA-IR were identified from GWAS meta-analysis of 46,186 non-diabetic participants from 21 studies with follow-up in up to 76,558 additional individuals of European ancestry ($P < 5.0 \times 10^{-8}$) [29]. Detailed information about the DIAGRAM and MAGIC consortia are showed in Supplementary Materials, Details of Studies and Participants.

All these SNPs were in different genomic regions and not in linkage disequilibrium with other SNPs in the same glyceic trait ($r^2 < 0.20$). We performed a look-up of these SNPs in Phenoscanner to evaluate whether these SNPs were associated with other diseases or traits at genome-wide significance level ($P < 5.0 \times 10^{-8}$) which may indicate potential pleiotropic effects [31]. We found that eight SNPs for type 2 diabetes, eight SNPs for fasting glucose, six SNPs for HbA1c and one SNP for HOMA- β were also associated with other diseases or traits, such as white blood cell count, neutrophil count, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, total cholesterol, self-reported hypertension, coronary artery disease,

Table 2. Characteristics of the GWAS used in this study.

| Phenotype | Consortium | Sample size | Ancestry | Genotype data | PMID |
|----------------------------|------------|---------------------------|----------|---------------------------------|--------------------|
| Exposure (glycemic traits) | | | | | |
| Type 2 diabetes | DIAGRAM | Up to 212,747 individuals | European | GWAS array and metabochip array | 22885922, 28566273 |
| Fasting glucose | MAGIC | Up to 133,010 individuals | European | GWAS array and metabochip array | 22885924 |
| Fasting insulin | MAGIC | Up to 108,557 individuals | European | GWAS array and metabochip array | 22885924 |
| HbA1c | MAGIC | Up to 123,491 individuals | European | GWAS array | 28898252 |
| HOMA- β | MAGIC | Up to 98,372 individuals | European | GWAS array | 20081858 |
| HOMA-IR | MAGIC | Up to 94,636 individuals | European | GWAS array | 20081858 |
| Outcomes | | | | | |
| Alzheimer's disease | IGAP | Up to 54,162 individuals | European | GWAS array | 24162737 |

HbA1c, hemoglobin A1c; HOMA- β , homeostasis model assessment - β -cell function; HOMA-IR, homeostasis model assessment -insulin resistance.

years of educational attainment, serum urate (Supplementary Table 1). After exclusion of these SNPs and one SNP (rs12621844) for HbA1c not found in outcome datasets, we used the remaining 43 SNPs for type 2 diabetes, 28 SNPs for fasting glucose, 19 SNPs for fasting insulin, 36 SNPs for HbA1c, 6 SNPs for HOMA- β and 2 SNPs for HOMA-IR as the instrument in the MR analysis. Supplementary Table 2 shows the characteristics and associations of these included SNPs with the corresponding glycemic traits.

Outcomes

Summary statistics for the associations between each glycemic trait- associated SNP and Alzheimer's disease were obtained from the open-access GWAS of the International Genomics of Alzheimer's Project (IGAP) [30]. In brief, IGAP is a large two-stage GWAS on individuals of European ancestry [30]. In the first stage, IGAP mate-analyzed association of 7,055,881 SNPs with Alzheimer's disease in a total of 17,008 Alzheimer's disease cases and 37,154 controls of European ancestry from four GWAS datasets. In the second stage, IGAP genotyped and tested 11,632 SNPs for association with Alzheimer's disease in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In that study, Alzheimer's Disease was defined as autopsy- or clinically-confirmed Alzheimer's Disease cases according to criteria, such as National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (Supplementary Materials, Details of Studies and Participants). We derived summarized data of the glycemic trait- associated SNPs from the dataset of stage 1 of the IGAP. The associations between each

SNP related to glycemic traits and Alzheimer's disease are presented in Supplementary Table 2.

Statistical analysis

Two-sample MR approaches were used to compute estimates of each glycemic trait- Alzheimer's disease association using summarized data of the SNP-glycemic trait and SNP-Alzheimer's disease associations. The causal effect for each glycemic trait was evaluated by IVW method in which SNP-outcome coefficients were modeled as a function of SNP-exposure coefficients weighted by the inverse-variance of genetic associations with the outcome, assuming all SNPs were valid instruments [32]. In sensitivity analyses, we also performed complementary MR analyses using the penalized robust IVW, MR-Egger, simple median, weighted median, weighted MBE and MR-PRESSO methods for the traits of type 2 diabetes, fasting glucose, fasting insulin, HbA1c and HOMA- β . Sensitivity analyses were not performed for HOMA-IR since these methods require more than 2 variants. The penalized robust methods improved the robustness by penalizing the weights of candidate instruments with heterogeneous ratio estimates and providing robustness to outliers by performing robust regression [33]. The MR-Egger method was performed by the same weighted linear regression as IVW method but with the intercept unconstrained. The slope coefficient from the MR-Egger regression is a robust estimate of the causal effect against potential violations of assumptions due to directional pleiotropy (genetic variants affect the outcome via a different biological pathway from the exposure) [24]. The weighted median method used the weighted median ratio estimate with less weight given to outlying estimates and can provide a robust estimate

even if up to 50% of instrumental variables are invalid [34]. The weighted MBE method used the mode of the IVW empirical density function as the effect estimate and can provide an estimate robust to horizontal pleiotropy [35]. The MR-PRESSO approach can detect and correct for pleiotropy via outlier removal in multi-instrument summary-level MR testing [36]. Heterogeneity between genetic variants was estimated by Q statistic in IVW method [34]. Potential pleiotropic effects were estimated by the values of intercept in MR-Egger regression. An intercept term that differs from zero indicates overall directional pleiotropy [24]. For the traits of fasting glucose and HOMA- β , we also performed a leave-one-out sensitivity analysis by leaving each genetic variant out of the MR analysis in turn to estimate the influence of outlying SNPs [37].

The associations between genetically predicted glycemic traits and Alzheimer's disease were presented as ORs with their 95% CIs per 1-unit-higher log-odds of type 2 diabetes, 1-SD higher fasting glucose, fasting insulin and HOMA-IR, %-units higher HbA_{1c}, and 1-SD lower HOMA- β (indicating pancreatic β -cell dysfunction), respectively. Trait values for fasting insulin, HOMA-IR and HOMA- β were naturally log transformed. The associations of each genetic variant with fasting glucose and HOMA- β were further plotted against their effects for the risk of Alzheimer's disease. The threshold of statistical significance was 2-sided p-value <0.05. All analyses were performed using R version 3.5.3 (R Development Core Team). All data generated or analyzed during this study are included in this published article.

AUTHOR CONTRIBUTIONS

YP designed the study, analyzed and interpreted of data, wrote the manuscript. WC interpreted data, revised the manuscript. HY, MW and XX: acquired the data, analyzed and interpreted of data.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This study is supported by grants from the National Natural Science Foundation of China (81971091, 81901177), Beijing Hospitals Authority Youth Programme (QML20190501), Ministry of Science and Technology of the People's Republic of China (2017YFC1310901, 2017YFC1310902, 2017YFC1307905, 2018YFC1311700 and 2018YFC1311706), Beijing Municipal Science and Technology Commission (D171100003017002), National Science and Technology Major Project (2017ZX09304018), Beijing Tiantan

Hospital (2018-YQN-1 and 2020MP01) and Young Elite Scientist Sponsorship Program (2019QNRC001).

REFERENCES

1. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet Neurol.* 2019; 18:88–106. [https://doi.org/10.1016/S1474-4422\(18\)30403-4](https://doi.org/10.1016/S1474-4422(18)30403-4) PMID:[30497964](https://pubmed.ncbi.nlm.nih.gov/30497964/)
2. Kuehn BM. In Alzheimer research, glucose metabolism moves to center stage. *JAMA.* 2020. [Epub ahead of print]. <https://doi.org/10.1001/jama.2019.20939> PMID:[31913419](https://pubmed.ncbi.nlm.nih.gov/31913419/)
3. Ninomiya T. Epidemiological evidence of the relationship between diabetes and dementia. *Adv Exp Med Biol.* 2019; 1128:13–25. https://doi.org/10.1007/978-981-13-3540-2_2 PMID:[31062323](https://pubmed.ncbi.nlm.nih.gov/31062323/)
4. Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA_{1c}, diabetes and cognitive decline: the english longitudinal study of ageing. *Diabetologia.* 2018; 61:839–48. <https://doi.org/10.1007/s00125-017-4541-7> PMID:[29368156](https://pubmed.ncbi.nlm.nih.gov/29368156/)
5. Marseglia A, Fratiglioni L, Kalpouzos G, Wang R, Bäckman L, Xu W. Prediabetes and diabetes accelerate cognitive decline and predict microvascular lesions: a population-based cohort study. *Alzheimers Dement.* 2019; 15:25–33. <https://doi.org/10.1016/j.jalz.2018.06.3060> PMID:[30114414](https://pubmed.ncbi.nlm.nih.gov/30114414/)
6. Ekblad LL, Rinne JO, Puukka P, Laine H, Ahtiluoto S, Sulkava R, Viitanen M, Jula A. Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample. *Diabetes Care.* 2017; 40:751–758. <https://doi.org/10.2337/dc16-2001> PMID:[28381479](https://pubmed.ncbi.nlm.nih.gov/28381479/)
7. Hooshmand B, Rusanen M, Ngandu T, Leiviskä J, Sindi S, von Arnim CA, Falkai P, Soininen H, Tuomilehto J, Kivipelto M. Serum insulin and cognitive performance in older adults: a longitudinal study. *Am J Med.* 2019; 132:367–73. <https://doi.org/10.1016/j.amjmed.2018.11.013> PMID:[30502316](https://pubmed.ncbi.nlm.nih.gov/30502316/)
8. James SN, Wong A, Tillin T, Hardy R, Chaturvedi N, Richards M. The effect of mid-life insulin resistance and type 2 diabetes on older-age cognitive state: the explanatory role of early-life advantage. *Diabetologia.* 2019; 62:1891–900. <https://doi.org/10.1007/s00125-019-4949-3> PMID:[31359084](https://pubmed.ncbi.nlm.nih.gov/31359084/)

9. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med*. 2008; 27:1133–63. <https://doi.org/10.1002/sim.3034> PMID:17886233
10. Li R, Zhang Y, Rasool S, Geetha T, Babu JR. Effects and underlying mechanisms of bioactive compounds on type 2 diabetes mellitus and Alzheimer's disease. *Oxid Med Cell Longev*. 2019; 2019:8165707. <https://doi.org/10.1155/2019/8165707> PMID:30800211
11. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. *J Cell Mol Med*. 2011; 15:1807–21. <https://doi.org/10.1111/j.1582-4934.2011.01318.x> PMID:21435176
12. Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: role of insulin signalling and therapeutic implications. *Int J Mol Sci*. 2018; 19:3306. <https://doi.org/10.3390/ijms19113306> PMID:30355995
13. De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer's disease? *Alzheimers Dement*. 2014; 10:S26–32. <https://doi.org/10.1016/j.jalz.2013.12.004> PMID:24529521
14. Willette AA, Xu G, Johnson SC, Birdsill AC, Jonaitis EM, Sager MA, Hermann BP, La Rue A, Asthana S, Bendlin BB. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. *Diabetes Care*. 2013; 36:443–49. <https://doi.org/10.2337/dc12-0922> PMID:23069842
15. Vergoossen LW, Schram MT, de Jong JJ, Stehouwer CD, Schaper NC, Henry RM, van der Kallen CJ, Dagnelie PC, van Boxtel MP, Eussen SJ, Backes WH, Jansen JF. White matter connectivity abnormalities in prediabetes and type 2 diabetes: the maastricht study. *Diabetes Care*. 2020; 43:201–08. <https://doi.org/10.2337/dc19-0762> PMID:31601638
16. Østergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JR, Boehme KL, Walter S, Kauwe JS, Gibbons LE, Larson EB, Powell JF, et al, and Alzheimer's Disease Genetics Consortium, and GERAD1 Consortium, and EPIC-InterAct Consortium. Associations between potentially modifiable risk factors and Alzheimer disease: a mendelian randomization study. *PLoS Med*. 2015; 12:e1001841. <https://doi.org/10.1371/journal.pmed.1001841> PMID:26079503
17. Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS, and CoSTREAM Consortium, on behalf of the International Genomics of Alzheimer's Project. Modifiable pathways in Alzheimer's disease: mendelian randomisation analysis. *BMJ*. 2017; 359:j5375. <https://doi.org/10.1136/bmj.j5375> PMID:29212772
18. Mehlig K, Lapidus L, Thelle DS, Waern M, Zetterberg H, Björkelund C, Skoog I, Lissner L. Low fasting serum insulin and dementia in nondiabetic women followed for 34 years. *Neurology*. 2018; 91:e427–35. <https://doi.org/10.1212/WNL.0000000000005911> PMID:29997193
19. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. *Diabetologia*. 2014; 57:1781–88. <https://doi.org/10.1007/s00125-014-3285-x> PMID:24891021
20. Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. *Epidemiol Psychiatr Sci*. 2020; 29:e118. <https://doi.org/10.1017/S2045796020000347> PMID:32326995
21. Benn M, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-Schmidt R. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals. *Diabetologia*. 2020; 63:1151–61. <https://doi.org/10.1007/s00125-020-05124-5> PMID:32172311
22. Walter S, Marden JR, Kubzansky LD, Mayeda ER, Crane PK, Chang SC, Cornelis M, Rehkopf DH, Mukherjee S, Glymour MM. Diabetic phenotypes and late-life dementia risk: a mechanism-specific Mendelian randomization study. *Alzheimer Dis Assoc Disord*. 2016; 30:15–20. <https://doi.org/10.1097/WAD.000000000000128> PMID:26650880
23. Gan W, Walters RG, Holmes MV, Bragg F, Millwood IY, Banasik K, Chen Y, Du H, Iona A, Mahajan A, Yang L, Bian Z, Guo Y, et al, and China Kadoorie Biobank Collaborative Group. Evaluation of type 2 diabetes genetic risk variants in Chinese adults: findings from 93,000 individuals from the China Kadoorie Biobank. *Diabetologia*. 2016; 59:1446–57. <https://doi.org/10.1007/s00125-016-3920-9> PMID:27053236
24. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015; 44:512–25. <https://doi.org/10.1093/ije/dyv080> PMID:26050253

25. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, et al, and Wellcome Trust Case Control Consortium, and Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators, and Genetic Investigation of ANthropometric Traits (GIANT) Consortium, and Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium, and South Asian Type 2 Diabetes (SAT2D) Consortium, and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet.* 2012; 44:981–90.
<https://doi.org/10.1038/ng.2383> PMID:[22885922](https://pubmed.ncbi.nlm.nih.gov/22885922/)
26. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, Pervjakova N, Pers TH, Johnson AD, Eicher JD, Jackson AU, Ferreira T, Lee Y, et al, and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. An expanded genome-wide association study of type 2 diabetes in europeans. *Diabetes.* 2017; 66:2888–902.
<https://doi.org/10.2337/db16-1253> PMID:[28566273](https://pubmed.ncbi.nlm.nih.gov/28566273/)
27. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Mägi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, et al, and DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat Genet.* 2012; 44:991–1005.
<https://doi.org/10.1038/ng.2385> PMID:[22885924](https://pubmed.ncbi.nlm.nih.gov/22885924/)
28. Wheeler E, Leong A, Liu CT, Hivert MF, Strawbridge RJ, Podmore C, Li M, Yao J, Sim X, Hong J, Chu AY, Zhang W, Wang X, et al, and EPIC-CVD Consortium, and EPIC-InterAct Consortium, and Lifelines Cohort Study. Impact of common genetic determinants of hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis. *PLoS Med.* 2017; 14:e1002383.
<https://doi.org/10.1371/journal.pmed.1002383> PMID:[28898252](https://pubmed.ncbi.nlm.nih.gov/28898252/)
29. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Mägi R, Morris AP, et al, and DIAGRAM Consortium, and GIANT Consortium, and Global BPgen Consortium, and Anders Hamsten on behalf of Procardis Consortium, and MAGIC investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010; 42:105–16.
<https://doi.org/10.1038/ng.520> PMID:[20081858](https://pubmed.ncbi.nlm.nih.gov/20081858/)
30. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, et al, and European Alzheimer’s Disease Initiative (EADI), and Genetic and Environmental Risk in Alzheimer’s Disease, and Alzheimer’s Disease Genetic Consortium, and Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat Genet.* 2013; 45:1452–58.
<https://doi.org/10.1038/ng.2802> PMID:[24162737](https://pubmed.ncbi.nlm.nih.gov/24162737/)
31. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, Paul DS, Freitag D, Burgess S, Danesh J, Young R, Butterworth AS. PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics.* 2016; 32:3207–09.
<https://doi.org/10.1093/bioinformatics/btw373> PMID:[27318201](https://pubmed.ncbi.nlm.nih.gov/27318201/)
32. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* 2013; 37:658–65.
<https://doi.org/10.1002/gepi.21758> PMID:[24114802](https://pubmed.ncbi.nlm.nih.gov/24114802/)
33. Burgess S, Bowden J, Dudbridge F, Thompson SG. Robust instrumental variable methods using multiple candidate instruments with application to Mendelian randomization. *arXiv.* 2016.
<https://arxiv.org/abs/1606.03729v2>
34. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol.* 2016; 40:304–14.
<https://doi.org/10.1002/gepi.21965> PMID:[27061298](https://pubmed.ncbi.nlm.nih.gov/27061298/)
35. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* 2017; 46:1985–98.
<https://doi.org/10.1093/ije/dyx102> PMID:[29040600](https://pubmed.ncbi.nlm.nih.gov/29040600/)
36. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* 2018; 50:693–8.
<https://doi.org/10.1038/s41588-018-0099-7> PMID:[29686387](https://pubmed.ncbi.nlm.nih.gov/29686387/)
37. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol.* 2017; 32:377–89.
<https://doi.org/10.1007/s10654-017-0255-x> PMID:[28527048](https://pubmed.ncbi.nlm.nih.gov/28527048/)

SUPPLEMENTARY MATERIALS

DETAILS OF STUDIES AND PARTICIPANTS

DIAbetes genetics replication and meta-analysis (DIAGRAM)

The DIAGRAM consortium is a grouping of researchers with shared interests in performing large-scale studies to characterize the genetic basis of type 2 diabetes (T2D), and a principal focus on samples of European descent. The membership and scope of DIAGRAM has developed as the scale of collaboration in the field has increased. The initial instance of DIAGRAM (retrospectively termed "DIAGRAM v1") enabled the combination of T2D genome wide association studies (GWAS) from the UK (WTCCC), DGI and FUSION groups. An incremental meta-analysis ("DIAGRAM v2" or "DIAGRAM+") added GWAS data from a further five studies (DGDG, KORA, Rotterdam, deCODE, EUROSPAN for a total of 8,130 cases and 38,987 controls) together with extensive replication involving 20 other cohorts. GWAS data from the Framingham, ARIC and NHS studies was only used for in silico replication, the full data from these studies was subsequently combined to constitute the largest current GWAS dataset in samples of European descent ("DIAGRAMv3": 12,171 cases and 56,862 controls). The present study combined the DIAGRAMv3 (stage 1) GWAS meta-analysis with a stage 2 meta-analysis comprising 22,669 cases and 58,119 controls genotyped with MetaboChip, including 1,178 cases and 2,472 controls of Pakistani descent (PMID: 22885922).

An expanded GWAS of T2D in Europeans were performed with a GWAS stage 1 and MetaboChip stage 2. The DIAGRAM stage 1 analyses comprised a total of 26,676 T2D cases and 132,532 control participants from 18 GWAS (ARIC, BioMe, deCODE, DGDG, DGI, EGCUT-370, EGCUT-OMNI, EPIC-InterAct, FHS, FUSION, GoDARTS, HPFS, KORAGEN, NHS, PIVUS, RS-I, ULSAM, WTCCC). The MetaboChip stage 2 follow up comprised 14,545 T2D case and 38,994 control subjects from 16 studies (D2D2007, DANISH, DIAGEN, DILGOM, DRsEXTRA, EMIL-Ulm, FUSION2, NHR, IMPROVE, InterACT-CMC, Leipzig, METSIM, HUNT/TROMSO, SCARFSHEEP, STR, Warren2/58BC) with MetaboChip data, in which the participants did not overlap those included in stage 1. Stage 1 study sizes ranged between 80 and 7,249 T2D cases and from 455 to 83,049 controls. The MetaboChip follow-up study sizes ranged from 101 and 3,553 T2D cases and from 586 to 6,603 controls. For SNVs not captured on MetaboChip directly or by proxy, follow-up in 2,796 individuals with T2D and 4,601 controls from the EPIC-InterAct study was performed. In addition, 9,747 T2D cases and 61,857 controls from the GERA

study were used to follow-up six low frequency variants not captured on MetaboChip. All study participants were of European ancestry and were from the United States and Europe (PMID: 28566273).

Meta-analyses of glucose and insulin-related traits consortium (MAGIC)

MAGIC represents a collaborative effort to combine data from multiple GWAS to identify additional loci that impact on glycemic and metabolic traits. MAGIC investigators have initially studied fasting glucose, fasting insulin, 2h glucose and HbA1c, as well as performed meta-analysis of more sophisticated measures of insulin secretion and sensitivity.

GWAS meta-analysis data results for fasting glucose are from models adjusted for age and sex, and from up to 133,010 non-diabetic participants of European ancestry from 66 studies. Fasting insulin results are for ln-transformed fasting insulin as the outcome and are adjusted for age, sex and are reported both with and without BMI adjustment, and from up to 108,557 individuals of European ancestry from 56 studies (PUBMED: 22885924).

Ancestry-specific and transethnic genome-wide meta-analysis summary statistics for association with HbA1c in up to 159,940 individuals from 82 cohorts of European (N=123,665), African (N=7,564), East Asian (N=20,838) and South Asian (N=8,874) ancestry. All participants were free of diabetes. HbA1c trait values are untransformed and adjusted for age, sex and study-specific covariates (PMID: 28898252). Only data of European ancestry were used in the present analysis.

The fasting insulin and fasting glucose datasets were generated by performing a meta-analysis of up to 21 genome-wide association studies (GWAS) informative for fasting glucose, fasting insulin and indices of β -cell function (HOMA- β) and insulin resistance (HOMA-IR) in up to 46,186 non-diabetic participants. Follow-up of 25 lead SNPs were performed in up to 76,558 additional individuals of European ancestry. Fasting glucose trait values are not transformed. Trait values for fasting insulin, HOMA-IR, HOMA- β and fasting proinsulin have been naturally log transformed. All datasets are adjusted for age, sex and study-specific covariates (PMID: 20081858).

International Genomics of Alzheimer's Project (IGAP)

IGAP is a large two-stage study based upon GWAS on individuals of European ancestry. In stage 1, IGAP used

genotyped and imputed data on 7,055,881 SNPs to meta-analyse four GWAS datasets with a total of 17,008 Alzheimer's disease cases and 37,154 controls (The Alzheimer Disease Genetics Consortium [ADGC], The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium [CHARGE], The European Alzheimer's disease Initiative [EADI], and The Genetic and Environmental Risk in AD consortium [GERAD]). In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. The present study used the dataset of stage 1 of the IGAP (PMID: 24162737).

The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips was funded by the French National

Foundation on Alzheimer's disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.

Supplementary Tables

Please browse Full Text version to see the data of Supplementary Table 2.

Supplementary Table 1. SNPs associated with other diseases or traits at genome-wide significance level ($P < 5.0 \times 10^{-8}$).

| Glycemic traits | SNP | Associated other diseases or traits |
|-----------------|------------|--|
| T2D | rs10203174 | Lymphocyte percentage of white cells, lymphocyte count |
| T2D | rs13389219 | Waist hip ratio, triglycerides, body mass index |
| T2D | rs2943640 | HDL cholesterol, triglycerides |
| T2D | rs7202877 | Coronary artery disease |
| T2D | rs10401969 | Total cholesterol, triglycerides, LDL cholesterol |
| T2D | rs9271774 | White blood cell count, lymphocyte count, neutrophil count |
| T2D | rs635634 | LDL cholesterol, total cholesterol, white blood cell count |
| T2D | rs2925979 | HDL cholesterol, adiponectin, self-reported hypertension |
| FG | rs983309 | Inflammation, total cholesterol, HDL cholesterol |
| FG | rs3829109 | Neutrophil count, white blood cell count, granulocyte count |
| FG | rs9368222 | Self-reported hypertension |
| FG | rs11715915 | Years of educational attainment |
| FG | rs17762454 | Serum urate, white blood cell count |
| FG | rs780094 | Triglycerides, serum urate, white blood cell count, C reactive protein |
| FG | rs7944584 | Self-reported hypertension |
| FG | rs174550 | Triglycerides, LDL cholesterol |
| HbA1c | rs7616006 | Lymphocyte count, monocyte count, total cholesterol, LDL cholesterol |
| HbA1c | rs9818758 | Years of educational attainment |
| HbA1c | rs1800562 | Self-reported hypertension |
| HbA1c | rs592423 | Reticulocyte count, triglycerides, HDL cholesterol |
| HbA1c | rs579459 | LDL cholesterol, total cholesterol, interleukin 6, coronary artery disease |
| HbA1c | rs10774625 | Lymphocyte count, self-reported hypertension, coronary artery disease, total cholesterol |
| HOMA- β | rs174550 | Triglycerides, LDL cholesterol, HDL cholesterol, white blood cell count |

SNP, single nucleotide polymorphism; T2D, type 2 diabetes; FG, fasting glucose; HbA1c, hemoglobin A1c; HOMA- β , homeostasis model assessment - β -cell function; LDL, low density lipoprotein; HDL, high density lipoprotein.

Supplementary Table 2. Characteristics of the SNPs associated with glycemic traits.